Nov 2, 2026 5 min read Milestone Monday Deals and Capital Markets

Milestone Monday: How Two Very Large Parties Helped Biotech’s IPO Year Reach $8.89bn

The count is far from 2021’s 107, but this year’s $306.6m average is the highest of the past seven years. Bambusa and Aspen, the latest two, came in under it.

Capsul Desk

Empty, set tables in a dimly lit restaurant, with black-and-white diner portraits on the wall above. — Fewer diners, fatter checks. *Picture by Yanhao Fang / Unsplash.*

Share Share Share Email

The Long View: When The First Reader Is A Machine

Trial Tuesday: On The Front Line

More on this topic

A pack of marathon runners seen from behind on a city street, some lit by low sun and others in shadow, with spectators and a brick apartment building in the background.

Milestone Monday: The Starting Gun Is Not The Finish Line

Oct 19, 2026 Aakash Babu 4 min read members

A reddish-brown retriever wearing black-framed glasses rests its chin on an open magazine, looking up at the camera.

Milestone Monday: Biopharma IPOs Are Playing To A Friendly House

Oct 5, 2026 Capsul Desk 6 min read members

The Long View: After 11 Years, 2 Months, 23 Days and One $62bn Deal, Weber Hands Takeda to Kim

Christophe Weber leaves a global top-ten drugmaker, and the debt it took to get there. The verdict now belongs to the executive who arrived in the very transaction that made it.

Jun 26, 2026 Capsul Desk 7 min read members

More from this edition

Sunlit Madrid street with traffic, period buildings and a domed landmark under scaffolding.

Milestone Monday: The Weekend Madrid Stood Up For Small Cell Lung Cancer

Oct 26, 2026 Capsul Desk 7 min read members

Two hands holding separate puzzle pieces up to the light, about to connect them against a blurred green background.

Milestone Monday: The Renewal And The Revolution

Oct 12, 2026 Aakash Babu 4 min read members

Milestone Monday: At BIO 2026, The Sellers Set The Pace

Money is everywhere and buyers are hungry, so biotechs are seeing several suitors at once and in no rush to commit. The complications: the most wanted assets keep turning up in China, and a US pricing rule means no deal abroad stays abroad.

Jun 29, 2026 Capsul Desk 6 min read members